Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Claudia Cardone

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

C. Cardone1, B. Blauensteiner2, V. Moreno-Viedma2, M.C. Paul2, G. Martini1, P.P. Vitiello1, D. Ciardiello1, C. Borrelli1, L. Poliero1, P. Vitale1, N. Zanaletti1, V. Famiglietti1, A.M. Rachiglio3, D. Rizzi4, E. Maiello5, T.P. Latiano5, N. Normanno3, M. Sibilia2, F. Ciardiello1, E. Martinelli1

Author affiliations

  • 1 Medical Oncology, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Institute Of Cancer Research, Medical University of Vienna, Vienna/AT
  • 3 Cell Biology And Biotherapy Unit, National Cancer Institute ‘Fondazione Giovanni Pascale’, Napoli/IT
  • 4 Clinical research, GOIM trial office, 80131 - Bari/IT
  • 5 Oncology, Hospital Casa Sollievo della Sofferenza-IRCCS, san giovanni rotondo/IT
More

Resources

Abstract 2300

Background

AXL expression promotes tumour growth, angiogenesis, epithelial to mesenchymal transition (EMT), resistance to CT and targeted agents. AXL is overexpressed in CRC. We aimed to evaluate AXL expression in mCRC pts and to correlate it with clinical outcomes.

Methods

AXL expression was assessed by immunohistochemistry in tumor samples of a consecutive series of 109 mCRC pts (75 RAS mutant and 34 RAS WT) treated at our Institution and 68 mCRC RAS WT pts enrolled in CAPRI-GOIM trial. Pts received a first line treatment according to RAS status: RAS mutant pts (n = 75) received CT + anti-angiogenic drugs, RAS WT pts (n = 102) CT + cetuximab.

Results

AXL stained positively in 20/177 samples with different intensity: 13 weak, 5 moderate, 2 intense. In RAS WT cohort 9/102 cases (9%) were positive while in RAS mutant 11/75 (15%). Tumor stroma was assessable in 166 samples. AXL expression was high (moderate + intense) in 47/96 (49%) RAS WT and in 28/70 (40%) RAS mutant cases. No significant correlation was found between AXL expression and clinico-patological features. In RAS WT cohort, AXL positive pts had a significantly worse median PFS [4.3 m (CI95% 3.2-5.5) vs 12.1 m (CI95% 11.0-13.3) p = 0.001], in RAS mutant no impact on PFS was observed. AXL expression in tumor was a negative prognostic factor in both cohorts although statistical significance was reached only in RAS mutant [median OS: 30.2 m (CI95% 18.4-42.0) vs 20.1 m (CI95% 10.6-29.6) p = 0.007]. Intriguingly, high AXL expression in stroma correlated with lower median OS in both cohorts (Table).Table: 96P

CohortMedian OS (months - CI95%) AXL expression in tumorMedian PFS (months - CI95%) AXL expression in tumorMedian OS (months - CI95%) AXL expression in stromaMedian PFS (months - CI95%) AXL expression in stroma
N (tumor) / N (stroma)AXL positiveAXL negativeAXL positiveAXL negativeAXL highAXL lowAXL highAXL low
Overall population N = 177 / N = 16620.1 (12.8-27.4)36.5 (30.6-42.3 ) p = 0.02--25.3 (21.4-29.3)46.4 (34.6-58.2) p = 0.003--
RAS WT (CT + cetuximab) N = 102 / N = 9623.0 (0.0- 63.3)39.8 (30.2– 49.4) p = 0.664.3 (3.2- 5.5)12.1 (11.0– 13.3) p = 0.00128.8 (17.4- 40.1)47.7 (29.7– 65.7) p = 0.02110.7 (8.4- 13.0)12.4 (9.6– 15.2) p = 0.06
RAS mutant (CT + anti-angiogenic) N = 75 / N = 7020.1 (10.6- 29.6)30.2 (18.4- 42.0) p = 0.0078.9 (5.4- 12.4)9.1 (7.6- 10.7) p = 0.44424.2 (18.2- 30.1)37.7 (16.8- 58.6) p = 0.0268.9 (6.1- 11.8)8.6 (7.3- 10.0) p = 0.53

Conclusions

AXL, marker of EMT phenotype, might represent an additional predictive biomarker of lack of efficacy in RAS WT mCRC pts treated with CT + cetuximab. Moreover, its expression in tumor and stroma might have a negative prognostic relevance in mCRC. Targeting AXL could overcome resistance to anti-epidermal growth factor receptor and represent a novel therapeutic strategy in mCRC.

Clinical trial identification

CAPRI-GOIM Trial = EudraCT 2009-014041-81.

Legal entity responsible for the study

Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli".

Funding

Grant by AIRC = MFAG-2015-ID: 7778.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings